A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients.

@article{Szelachowska1997APS,
  title={A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients.},
  author={Malgorzata Szelachowska and Anna Maria Poplawska and Jolanta Topolska and I. Kinalska and Maria Grimaldi},
  journal={Current medical research and opinion},
  year={1997},
  volume={13 9},
  pages={
          539-45
        }
}
Fifteen out-patients with type I diabetes mellitus and microalbuminuria (mean +/- SEM: 95.4 +/- 13.9 micrograms/min), were administered the glycosaminoglycan sulodexide, with the aim of investigating its influence on the rate of albumin excretion. Sulodexide was given intramuscularly in a dose of 600 lipoproteinlipase releasing units/day for three weeks. Albumin excretion was measured before dosing, at weekly intervals during dosing and also during the subsequent follow-up period of six weeks… 
Anti-Proteinuric Effect of Sulodexide in Immunoglobulin A Nephropathy
TLDR
A 6-month treatment with sulodexide did not achieve 50% reduction of urinary protein excretion in IgA nephropathy patients, but showed a tendency to increase the time-dependent anti-proteinuric effect.
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.
TLDR
The data do not suggest a renoprotective benefit of sulodexide in patients with type 2 diabetes, renal impairment, and macroalbuminuria, and side effect profiles were similar for both groups.
Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial.
TLDR
A 4-mo course of high doses of sulodexide significantly and dose-dependently improves albuminuria in DM1 and DM2 patients and micro- or macroalbuminuric patients with or without concomitant ACE inhibition.
The Role of Glycosaminoglycans and Sulodexide in the Treatment of Diabetic Nephropathy
TLDR
Treatment with glycosaminoglycans, and with sulodexide in particular, significantly improves albuminuria in type 1 and type 2 diabetic patients with micro- or macroalbuminuria, strongly suggesting that favorable chemical and anatomic remodeling is induced by exogenous glycosamination in renal tisues, as observed in the experimental model.
The Role of Sulodexide in the Treatment of Diabetic Nephropathy
TLDR
An emerging body of evidence supports the notion that glomerular capillary wall and mesangial alterations in diabetic nephropathy involve pathobiochemical alterations of glycoproteins in these structures.
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
TLDR
Sulodexide development as an antiproteinuric drug needs to be continued, in order to define which kind of patients could better respond to this treatment, and to improve the prognosis of chronic kidney disease patients.
Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry
TLDR
Sulodexide was effective in reducing recurrent thrombotic events in high-risk subjects and was comparable for age and sex distribution and for the localization of the thrombi at inclusion.
Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans
TLDR
Evidence supporting the potential nephroprotective effects of sulodexide and other glycosaminoglycans is discussed, potentially useful to reduce the renal damage and the cardiovascular disease associated with proteinuria.
Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis
TLDR
Sulodexide has a beneficial effect on the ocular, peripheral arterial disease, trophic ulcers, and renal complications of diabetes without increasing the risk of AEs.
...
...

References

SHOWING 1-10 OF 14 REFERENCES
Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy.
TLDR
It is demonstrated that long-term administration of glycosaminoglycans prevents renal morphological and functional alterations in diabetic rats and appears to revert established diabetic renal lesions.
Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats.
TLDR
It is demonstrated that the long-term administration of glycosaminoglycans has a favorable effect on morphological and functional renal abnormalities in diabetic rats.
Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide.
TLDR
An altered fibrinolytic response to increased thrombin activation in Type 1 diabetic patients is shown and it is suggested that the administration of the glycosaminoglycan, Sulodexide, may help to reduce this phenomenon.
Epidemiology of Persistent Proteinuria in Type II Diabetes Mellitus: Population-Based Study in Rochester, Minnesota
TLDR
Stratified analysis of the two most significant risk factors (fasting blood glucose and age) indicated that hyperglycemia was a stronger risk factor for proteinuria in younger diabetic subjects, perhaps because of a competing risk of death in the elderly diabetic patient.
The natural history and epidemiology of diabetic nephropathy. Implications for prevention and control.
TLDR
From this review, a strategy for preventing and controlling this important cause of morbidity is outlined and the evidence for efficacy of preventive and therapeutic measures is reviewed.
Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus.
Heparan sulfate proteoglycans (HSPG) are negatively charged constituents of the renal extracellular matrix including the glomerular basement membrane (GBM) and mesangial matrix. Biochemical and
...
...